Can you summarize the IMPROVE‑IT trial—its LDL‑C management findings, the drug (ezetimibe) and dose, the patient population (adults with recent acute coronary syndrome on moderate‑intensity simvastatin), and the results?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

IMPROVE-IT Trial Summary: LDL Management with Ezetimibe After Acute Coronary Syndrome

The IMPROVE-IT trial definitively established that adding ezetimibe 10 mg daily to simvastatin 40 mg in patients stabilized after acute coronary syndrome reduces major cardiovascular events by 6.4% relative risk over 6 years, with the greatest benefit in diabetic patients who achieved a 5.5% absolute risk reduction. 1

Trial Design & Patient Population

  • 18,144 adults ≥50 years hospitalized for acute coronary syndrome within 10 days (median 5 days to randomization) were enrolled in this double-blind, randomized controlled trial 1, 2
  • The cohort comprised 29% STEMI and 71% unstable angina/NSTEMI patients; 34% were already receiving statin therapy at the time of their ACS event 1
  • Eligibility required baseline LDL-C ≥70 mg/dL (or 50-100 mg/dL if already on lipid-lowering therapy), with a mean baseline LDL-C of 93.8 mg/dL 1
  • Patients were followed for a median of 6 years (up to 7 years in some analyses) 1, 3

Drug Regimen & Dosing

  • Intervention arm: Ezetimibe 10 mg + simvastatin 40 mg once daily 1, 2
  • Control arm: Placebo + simvastatin 40 mg once daily 1
  • If consecutive LDL-C measurements exceeded 79 mg/dL at follow-up, simvastatin was uptitrated to 80 mg in a double-blind manner 2
  • Ezetimibe mechanism: Blocks intestinal cholesterol absorption via the NPC1L1 protein, typically yielding a 15-25% additional LDL-C reduction when added to statin therapy 1, 4

LDL-C Lowering Achieved

  • At 1 year, ezetimibe produced a 24% greater LDL-C reduction compared with placebo 1
  • On-treatment LDL-C levels: 53.2 mg/dL in the ezetimibe group versus 69.9 mg/dL in the control group 5, 1
  • The absolute LDL-C reduction from baseline was 16.7 mg/dL in men and 16.4 mg/dL in women at 12 months 6
  • Final achieved LDL-C in the combination arm was 1.4 mmol/L (53 mg/dL) versus 1.8 mmol/L (70 mg/dL) in the simvastatin monotherapy arm 3

Primary Cardiovascular Outcomes

  • The primary composite endpoint (cardiovascular death, non-fatal MI, unstable angina rehospitalization, coronary revascularization ≥30 days, or non-fatal stroke) was reduced with a hazard ratio of 0.936 (95% CI 0.887-0.996; p=0.016) 1, 3
  • This translates to a 6.4% relative risk reduction and an approximately 2% absolute risk reduction over 6 years 1
  • When total recurrent cardiovascular events were analyzed, ezetimibe reduced events by 9% (incidence-rate ratio 0.91; 95% CI 0.85-0.97; p=0.007) 1
  • The benefit manifested early after the index ACS and persisted throughout the entire 6-year follow-up period 1

High-Risk Subgroup Benefits

Diabetes Mellitus (Greatest Benefit)

  • Diabetic patients achieved a 5.5% absolute risk reduction over 7 years (event rates 40.0% vs 45.5%; HR 0.85,95% CI 0.78-0.94) with a significant interaction (p=0.02) 1, 7
  • The LDL-C reduction was greater in diabetic patients than in those without diabetes 7
  • Cardiovascular morbidity and mortality were significantly decreased in diabetic patients, whereas the reduction in non-diabetic patients did not reach statistical significance 7

Women vs. Men

  • Women experienced a 12% risk reduction (HR 0.88; 95% CI 0.79-0.99) compared with a 5% reduction in men (HR 0.95; 95% CI 0.90-1.01; P=0.26 for interaction) 6
  • When total events were considered, women had an 18% reduction (RR 0.81; 95% CI 0.71-0.94) and men had a 6% reduction (RR 0.94; 95% CI 0.87-1.02; P=0.08 for interaction) 6

Other High-Risk Groups

  • Significant benefits were also observed in patients with prior coronary artery bypass graft, history of stroke, polyvascular disease, low baseline LDL-C, renal dysfunction, and prior heart failure 1, 8

Consistency Across Baseline LDL-C Levels

  • The treatment effect was consistent regardless of baseline LDL-C: HR 0.92 (50-<70 mg/dL), HR 0.93 (70-<100 mg/dL), HR 0.94 (100-125 mg/dL); interaction p=0.95 1

Safety Profile

  • Adding ezetimibe to simvastatin did not increase adverse-event rates compared with placebo 1, 8
  • Safety was comparable across all high-risk subgroups, including women and men 1, 6
  • No safety concerns emerged even when median LDL-C fell to 53 mg/dL, and the regimen was well-tolerated over the full 6-year period 1
  • Common adverse events (upper respiratory tract infection, diarrhea, arthralgia, sinusitis) occurred at rates similar to placebo 4
  • Ezetimibe has minimal drug-drug interaction potential because it does not significantly affect cytochrome P450 enzymes 4

Current ACC/AHA Guideline Recommendations (2025)

Class I (Should Be Done)

  • In ACS patients with LDL-C ≥70 mg/dL on maximally tolerated statin therapy, add a non-statin agent (including ezetimibe) to reduce major adverse cardiovascular events 5, 1

Class IIa (Reasonable)

  • For ACS patients on maximally tolerated statin with LDL-C 55-69 mg/dL, adding ezetimibe is reasonable to further lower MACE risk, especially in high-risk groups (diabetes, elderly, high TIMI score, polyvascular disease) 1

Class IIb (May Be Considered)

  • Concurrent initiation of ezetimibe with a maximally tolerated statin at the time of ACS hospitalization may be considered to accelerate achievement of LDL-C goals 1

Clinical Implementation Algorithm

Step 1: Statin Initiation/Intensification

  • If not already on a high-intensity statin, start atorvastatin 40-80 mg or rosuvastatin 20-40 mg before hospital discharge 5, 1
  • Note: IMPROVE-IT used moderate-intensity simvastatin 40 mg, but current guidelines recommend high-intensity statin first 1

Step 2: Lipid Reassessment

  • Check fasting lipid panel 4-8 weeks post-discharge 1

Step 3: LDL-C ≥70 mg/dL on Maximally Tolerated Statin

  • Add ezetimibe 10 mg daily (Class I recommendation) 5, 1
  • Anticipate an additional 15-25% LDL-C reduction 1, 4
  • Goal: LDL-C <55 mg/dL 1

Step 4: LDL-C 55-69 mg/dL on Maximally Tolerated Statin

  • Adding ezetimibe is reasonable (Class IIa), particularly in diabetic patients, elderly, or those with polyvascular disease 1

Step 5: LDL-C ≥70 mg/dL Despite Statin + Ezetimibe

  • Consider a PCSK9 inhibitor (evolocumab or alirocumab) for an additional 50-60% LDL-C reduction 1

Critical Pitfalls to Avoid

  • DO NOT de-escalate high-intensity statin therapy even when LDL-C falls to ~53 mg/dL; safety data show no adverse signal at very low LDL-C levels 1
  • DO NOT delay ezetimibe in diabetic ACS patients with LDL-C ≥70 mg/dL, as they achieve the greatest absolute benefit (5.5% reduction over 7 years) 1, 7
  • DO NOT assume lack of benefit in patients with baseline LDL-C <70 mg/dL; IMPROVE-IT demonstrated consistent benefit even in the 50-<70 mg/dL stratum 1
  • DO NOT use niacin as an add-on therapy; the AIM-HIGH trial showed that adding extended-release niacin to simvastatin plus ezetimibe improved lipid profiles but did not reduce cardiovascular events and increased adverse effects 1
  • DO NOT dose ezetimibe concurrently with bile-acid sequestrants; administer ezetimibe at least 2 hours before or 4 hours after the sequestrant to avoid reduced bioavailability 4

Evidence Quality Assessment

  • The IMPROVE-IT trial was double-blind, adequately powered, with appropriate randomization 1
  • The only limitation was a 19% loss to follow-up, classified as a mild relevance deficiency 1
  • Inclusion of total-event analyses more than doubled the number of events prevented, driven by reductions in non-fatal MI (RR 0.87; p=0.004) and non-fatal stroke (RR 0.77; p=0.005) 1

References

Guideline

Ezetimibe Added to Statin Therapy After Acute Coronary Syndrome: Evidence and Guideline Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Ezetimibe Clinical Efficacy and Safety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.